Business Context and Reporting Period
This Form 8-K Current Report was filed by Alnylam Pharmaceuticals, Inc. on February 15, 2012. The report addresses a specific event occurring on the same date regarding the company's public offering of common stock.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the exercise of an underwriters' option:
- Additional Shares Purchased: 1,125,000 shares of common stock.
- Public Offering Price: $10.75 per share.
Material Changes
The material change reported is the full exercise of the underwriters' option to purchase additional shares in the company's previously announced public offering. This action increases the total number of shares sold in the offering by 1,125,000 units at the established price of $10.75 per share.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies beyond the specific transaction details. The document serves strictly to disclose the completion of the share purchase option exercise.
Investor Verification Checklist
- Verify the total gross proceeds generated from the 1,125,000 additional shares (1,125,000 shares x $10.75).
- Confirm the total aggregate number of shares sold in the offering after the option exercise by reviewing the initial prospectus.
- Review the attached Press Release (Exhibit 99.1) for any additional context regarding the use of proceeds or market conditions.